Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Stopped The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.

Conditions

• Lymphocytic Leukemia, Chronic
• Lymphoma, Small Lymphocytic

Interventions

• DRUG: IPI-145 (duvelisib)
• DRUG: Obinutuzumab

Sponsor

SecuraBio